The Visual Illusion of Efficacy in Psychiatric Drug Trials

This article by Robert Whitaker has been published by Mad in America. It begins:

“Published reports of clinical trials of psychiatric drugs typically include a graphic showing the efficacy of the study drug in reducing symptoms of the disorder compared with placebo. These graphics are visually compelling. They almost always show a notable separation between the study drug and placebo in the reduction of symptoms over time, and thus the reader can see what the authors of the study conclude: The study drug, at one dose or another, is an effective treatment for the disorder.

These graphics, however, are presenting an illusion of efficacy. It’s done very simply: The graphics are set up with a vertical axis that, in essence, acts as a magnifying glass.

In a recent MIA Report titled Anatomy of an Industry: Commerce, Payments to Psychiatrists, and Betrayal of the Public Good, Mad in America looked at the financial influences present as seven new psychotropics were brought to market from 2013 through 2017: four antipsychotics, one antidepressant, and two drugs for tardive dyskinesia. The published reports of the pivotal trials of these drugs regularly featured a graphical illusion of this sort, an illusion that can be revealed by re-graphing the efficacy data with a proper vertical axis.

Here are the graphics that tell of this illusion of efficacy for each of the seven drugs, along with similar graphics for a fifth antipsychotic that was approved in 2020 (lumateperone) …”

You can read more from here.

Rate this post

Any reply would be very welcome


Get the latest posts delivered to your mailbox:

Your email address will not be passed to any other organisation. It will only be used to send you new posts made on this website.